WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Batavia Biosciences
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Medical
Peptilogics | January 11, 2022
Peptilogics, a biotech company that engineers peptide therapeutics to radically improve the treatment landscape for patients with life-threatening diseases, announced that the U.S. Food and Drug Administration as accepted the company's Investigational New Drug Application for PLG0206 to treat periprosthetic joint infection allowing the Phase 1b study to proceed. Peptilogics will evaluate the safety and efficacy of PLG0206 in a Phase 1b open-label, dose-escalating study i...
MedTech
Sequence Bio | April 08, 2022
Sequence Bio, a Newfoundland and Labrador-based discovery biology company, announced today that it has entered into a collaboration agreement with Danish dermatology specialists LEO Pharma, for use of Sequence Bio's proprietary discovery platform to identify novel dermatologic drug targets. Under the terms of the three year agreement, Sequence Bio will perform multi-omic analyses of samples from powered discovery cohorts across multiple dermatologic indications. LEO Pharma will leverage insi...
Cell and Gene Therapy, Industry Outlook
Businesswire | July 17, 2023
Slingshot Biosciences, Inc. a leading provider of cell mimic control products, is proud to announce the launch of its new SpectraComp fluorescent protein series collection. This groundbreaking series provides scientists with a cutting-edge fluorescent protein control platform for use in flow cytometry analysis. By genetically modifying T cells and other immune cells in humanized mice to express fluorescent reporter proteins, including eGFP and mCherry, scientists are able to obs...
PRNewswire | August 04, 2023
BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, and bit.bio, the company coding human cells for novel cures, today announced a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T cells (Tregs) for use in creating therapeutics. "Tregs play a crucial role in maintaining balance in the body's immune system and controlling excessive immune reactions...
MedTech, Industrial Impact
Whitepaper
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE